No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients

Transplant Proc. 2002 Dec;34(8):3165-7. doi: 10.1016/s0041-1345(02)03585-6.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Cyclosporine / therapeutic use
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Graft Survival / immunology
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Isoantibodies / blood
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality
  • Muromonab-CD3 / therapeutic use*
  • Patient Selection
  • Prednisone / therapeutic use
  • Survival Analysis
  • Time Factors
  • Transplantation, Homologous / immunology

Substances

  • Immunosuppressive Agents
  • Isoantibodies
  • Muromonab-CD3
  • Cyclosporine
  • Prednisone